Publications by authors named "Frans Erdkamp"

Claim this Profile
F
First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases: Post Hoc Analysis of the CAIRO5 Randomized Clinical Trial.
Marinde J G Bond, Karen Bolhuis, Olaf J L Loosveld, Jan Willem B de Groot, Helga Droogendijk, Frans Erdkamp

JAMA Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol.
Laurien J Zeverijn, Birgit S Geurts, Thomas W Battaglia, Jade M van Berge Henegouwen, Gijs F de Wit, Frans L G Erdkamp

Clin Cancer Res· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+ metastatic breast cancer: an analysis of the SONABRE registry.
Sandra M E Geurts, Khava I E Ibragimova, Nan Ding, Marissa Meegdes, Frans Erdkamp

Breast Cancer Res Treat· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab Resistance in Patients With HER2-Positive Advanced Breast Cancer: Results From the SONABRE Registry.
Khava I E Ibragimova, Sandra M E Geurts, Dávid Laczkó, Marissa Meegdes, Frans Erdkamp

Clin Breast Cancer· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prognostic impact of BMI in patients with HR+/HER2- advanced breast cancer: a study of the SONABRE registry.
Senna W M Lammers, Hannah Thurisch, Ingeborg J H Vriens, Marissa Meegdes, Sanne M E Engelen, Frans L G Erdkamp

Breast Cancer Res Treat· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer.
Senna W M Lammers, Sandra M E Geurts, Irene E G van Hellemond, Astrid C P Swinkels, Carolien H Smorenburg, Frans L G Erdkamp

JNCI Cancer Spectr· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group.
Marinde J G Bond, Karen Bolhuis, Olaf J L Loosveld, Jan Willem B de Groot, Helga Droogendijk, Frans Erdkamp

Lancet Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry.
Khava I E Ibragimova, Sandra M E Geurts, Marissa Meegdes, Frans Erdkamp, Joan B Heijns

Breast Cancer Res Treat· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended adjuvant aromatase inhibition after sequential endocrine therapy in postmenopausal women with breast cancer: follow-up analysis of the randomised phase 3 DATA trial.
Vivianne C G Tjan-Heijnen, Senna W M Lammers, Sandra M E Geurts, Ingeborg J H Vriens, Astrid C P Swinkels, Frans L G Erdkamp

EClinicalMedicine· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.
Birgit S Geurts, Thomas W Battaglia, J Maxime van Berge Henegouwen, Laurien J Zeverijn, Gijs F de Wit, Frans G L Erdkamp

BMC Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2- metastatic breast cancer: an observational study of the SONABRE Registry.
Marissa Meegdes, Sandra M E Geurts, Frans L G Erdkamp, M Wouter Dercksen, Birgit E P J Vriens

Lancet Reg Health Eur· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer.
Anouk K M Claessens, Jan J V Busschbach, Bram L T Ramaekers, Frans L G Erdkamp, Jeanette M Bouma

Acta Oncol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry.
Marissa Meegdes, Khava I E Ibragimova, Dorien J A Lobbezoo, Ingeborg J H Vriens, Loes F S Kooreman, Frans L G Erdkamp

Breast Cancer Res Treat· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment.
Louisa R Hoes, Jade M van Berge Henegouwen, Hanneke van der Wijngaart, Laurien J Zeverijn, Daphne L van der Velden, Frans Erdkamp

Clin Cancer Res· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2- advanced breast cancer patients: A study of the Dutch SONABRE Registry.
Marissa Meegdes, Sandra M E Geurts, Frans L G Erdkamp, Marcus Wouter Dercksen, Birgit E P J Vriens

Int J Cancer· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry.
Khava I E Ibragimova, Sandra M E Geurts, Sander Croes, Frans Erdkamp, Joan B Heijns

Breast Cancer Res Treat· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An economic evaluation of eribulin for advanced breast cancer treatment based on the Southeast Netherlands advanced breast cancer registry.
Xavier G L V Pouwels, Bram L T Ramaekers, Sandra M E Geurts, Frans Erdkamp, Birgit E P J Vriens

Acta Oncol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practice.
Anouk K M Claessens, Khava I E Ibragimova, Sandra M E Geurts, Monique E M M Bos, Frans L G Erdkamp

Crit Rev Oncol Hematol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Variability of cost trajectories over the last year of life in patients with advanced breast cancer in the Netherlands.
Paul P Schneider, Xavier G L V Pouwels, Valéria Lima Passos, Bram L T Ramaekers, Sandra M E Geurts, Frans Erdkamp

PLoS One· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer.
Anouk K M Claessens, Frans L G Erdkamp, Marta Lopez-Yurda, Jeanette M Bouma, Jeany M Rademaker-Lakhai

Acta Oncol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial.
Irene E G van Hellemond, Carolien H Smorenburg, Petronella G M Peer, Astrid C P Swinkels, Caroline M Seynaeve, Frans L G Erdkamp

Breast Cancer Res Treat· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancer.
Anouk K M Claessens, Reinier Timman, Jan J Busschbach, Jeanette M Bouma, Jeany M Rademaker-Lakhai, Frans L G Erdkamp

Breast Cancer Res Treat· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial.
Sophie A Kurk, Petra H M Peeters, Bram Dorresteijn, Pim A de Jong, Marion Jourdan, Frans L G Erdkamp

Cancer Med· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study.
Irene E G van Hellemond, Carolien H Smorenburg, Petronella G M Peer, Astrid C P Swinkels, Caroline M Seynaeve, Frans L G Erdkamp

Int J Cancer· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients.
Sophie Kurk, Petra Peeters, Rebecca Stellato, B Dorresteijn, Pim de Jong, Frans Erdkamp

J Cachexia Sarcopenia Muscle· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis